Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-04-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
民生证券股份有限公司关于杭州安旭生物科技股份有限公司2023年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导跟踪报告" which translates to "2023 Annual Continuous Supervision Follow-up Report" issued by a sponsoring institution (民生证券股份有限公司) for a listed company (杭州安旭生物科技股份有限公司). It references regulatory frameworks related to securities issuance, listing rules, and continuous supervision guidelines by the Shanghai Stock Exchange. The content includes detailed descriptions of ongoing supervision activities, risk factors, financial data, and corporate governance oversight for the year 2023. It is a comprehensive report on the continuous supervision work performed by the sponsor post-listing, including financial and operational risk disclosures, but it is not a full annual report of the company itself. This type of document is typically classified as an Audit Report / Information (AR) because it relates to regulatory compliance, supervisory activities, and audit-like oversight rather than the company’s own annual report (10-K) or interim report (IR). The document length is substantial (15,000 characters), and it contains substantive content rather than just an announcement or certification. Therefore, the best fitting category is AR (Audit Report / Information). FY 2023
2024-04-29 Chinese
安旭生物2023年年度报告
Annual Report Classification · 100% confidence The document is titled '2023 年年度报告' which translates to '2023 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, governance, and other comprehensive information typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial statements, auditor's opinion, and signatures from company officers, which are characteristic of an official annual report. The presence of detailed financial metrics, management commentary, and corporate governance sections confirms this classification. Therefore, the document is classified as an Annual Report (10-K equivalent). FY 2023
2024-04-29 Chinese
2023年度独立董事述职报告（章国标）
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It details the independent director's background, attendance at board and shareholder meetings, communication with auditors, oversight of financial reports, and other governance-related activities during the year 2023. The content focuses on the independent director's duties, evaluations, and governance oversight rather than presenting financial statements or audit results themselves. The document length is 4466 characters, which is relatively short and reads like a formal report or statement by an independent director rather than a full annual report or audit report. It is not a certification or a brief announcement but a detailed director's report on their activities and observations. This fits best under the category of Board/Management Information (MANG), as it relates to the independent director's report on their role and governance activities during the year.
2024-04-29 Chinese
董事会审计委员会2023年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee of Hangzhou Anxu Biotechnology Co., Ltd. for the year 2023. It discusses the committee's composition, meetings held, supervision of external audit firms, internal audit guidance, review of financial reports, internal control evaluation, and overall assessment of the committee's performance. The content focuses on audit-related activities and oversight rather than presenting full financial statements or a standalone audit opinion report. It is not an Annual Report (10-K) or an Interim Report (IR) because it does not contain comprehensive financial statements. It is not a simple announcement or certification but a substantive report on audit committee activities and audit oversight. This fits the definition of an Audit Report / Information (AR) filing, which includes audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document length (2577 characters) and detailed content support this classification with high confidence. FY 2023
2024-04-29 Chinese
安旭生物2023年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled '2023 年度业绩快报公告' which translates to '2023 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2023, including revenue, profit, net income, earnings per share, and asset information. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the company's 2023 Annual Report. The document is relatively short (2515 characters) and serves as a quick financial performance update rather than a full comprehensive report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and is preliminary. It is also not a Report Publication Announcement (RPA) because it contains actual financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2023
2024-02-28 Chinese
安旭生物2023年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast (业绩预告) from Hangzhou Anxu Biotechnology Co., Ltd. It provides preliminary estimated net profit figures for the full year 2023, comparing them to the prior year, and includes a risk warning and explanation of the profit decline. It explicitly states that the data is preliminary and unaudited, and that the final audited financial data will be disclosed in the formal 2023 annual report. The document length is short (1218 characters) and it is clearly a forecast or earnings guidance rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, not a full annual report or audited financial statements. FY 2023
2024-01-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.